NeoGenomics (NEO) has drawn fresh attention after appointing Carolyn Starrett to its Board of Directors, bringing her extensive experience in AI driven data insights and cancer care to the company’s governance.

Against this backdrop, NeoGenomics’ momentum has been strong, with a 90 day share price return of 82.38% and a 1 year total shareholder return of 97.16%, while 3 and 5 year total shareholder returns remain weak.

If you’re assessing how AI and healthcare themes are playing out beyond NeoGenomics, it may be worth scanning for other opportunities via 40 healthcare AI stocks.

With NeoGenomics shares up sharply over the past year and trading only about 3% below the average analyst price target, the key question now is whether the recent gains leave real upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 3% Undervalued

NeoGenomics last closed at $14.59, while the most followed narrative pegs fair value at $15.06. The story here hinges on how growth, margins and valuation assumptions fit together.

The commercial launch of PanTracer, a comprehensive liquid biopsy panel for therapy selection, is set to enhance NeoGenomics' competitiveness and capture greater share in the rapidly growing NGS and liquid biopsy segment, supporting revenue acceleration and higher average unit prices (AUP) through 2025 and beyond.

Read the complete narrative. Read the complete narrative.

Curious what sits behind that fair value label? This narrative leans on steady top line expansion, a meaningful swing in profit margins and a future earnings multiple that assumes investors stay confident. The exact mix of growth, profitability and discount rate assumptions is where the real story is hiding.

Result: Fair Value of $15.06 (UNDERVALUED)

However, the bullish NeoGenomics narrative still faces pressure from ongoing losses and intense competition in oncology testing, and any stumble here could quickly challenge that 3% undervalued label.

Another View: NeoGenomics and the Price to Sales Gap

The most popular NeoGenomics narrative leans on future earnings power, but the current price also sends a clear message. On a P/S of 2.5x, NeoGenomics trades well above both the US Healthcare industry average of 1.3x and its own fair ratio estimate of 1.5x. This points to valuation risk if expectations cool.

That kind of gap can close in different ways, so the real question is whether you think the business will grow into this higher multiple or if the multiple is more likely to move toward the fair ratio.

Next Steps

If this NeoGenomics story appears finely balanced between opportunity and risk, consider promptly reviewing the underlying data and stress testing your own thesis. A useful place to start is by checking the 1 important warning sign.

Looking for more investment ideas beyond NeoGenomics?

NeoGenomics may be front of mind today, but your next opportunity could be hiding in plain sight, and a few minutes of focused screening can make a real difference.

• Spot potential mispricings early by scanning 43 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect their underlying strength.
• Prioritise resilience by reviewing 74 resilient stocks with low risk scores that score well on financial stability and help keep portfolio volatility in check.
• Get ahead of the crowd by searching the screener containing 19 high quality undiscovered gems before the broader market starts paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.